eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2022-09-29 15 3 1311 1321 10.13005/bpj/2468 45253 article Giorgio Attina 1 Silvia Triarico 1 Alberto Romano 1 Palma Maurizi 1 Stefano Mastrangelo 1 Antonio Ruggiero 1 Pediatric Oncology Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Rome, Italy. Anthracyclines are routinely used in cancer chemotherapy in many childhood cancers. A serious adverse effect of doxorubicin chemotherapy is cardiotoxicity which may lead to congestive heart failure for long-term survivors years after treatment. Currently, echocardiography is used to control the heart function during anthracyclines therapy. B-type natriuretic peptide (BNP) and NT-proBNP as well as cardiac troponins have been proposed as clinical markers for subclinical anthracycline-induced cardiotoxicity. The BNP and pro-BNP can be easily measured in plasma and initial data indicate that the NT-proBNP could be sensitive predictor for the development of congestive heart failure. https://biomedpharmajournal.org/vol15no3/serum-biomarkers-for-the-detection-of-cardiac-dysfunction-in-childhood-cancers-receiving-anthracycline-based-treatment/ Anthracyclines  Children  pro-BNP  Troponin